FMO2 Promotes Angiogenesis via Regulation of N‐Acetylornithine
Advanced Science · 2025-12 · 12 (48)
DOI: 10.1002/advs.202506618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 06.10.2025. Verfasst von Jingyi Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China. Hauptthemen laut MEDLINE: Oxygenases, Neovascularization, Physiologic, Ornithine, Ischemia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Central Guidance on Local Science and Technology Development Fund of Zhejiang Province.
Abstract (Originalsprache)
Endothelial cell (EC) metabolism is an emerging target for proangiogenic treatment of ischemic diseases; however, little is known about the metabolic alterations in ECs during ischemic diseases or vessel development stages. By conducting single‐cell transcriptome analysis, this work identifies flavin‐containing monooxygenase 2 (FMO2) as a pivotal regulator under multiple ischemic conditions. Targeted EC compensation of FMO2 in the genetic ablation model proved its proangiogenic function in various ischemic models and in the developing retina. Metabolomics combined with EC single‐cell sequencing revealed N‐acetylornithine as the top‐ranked altered metabolite regulated by FMO2, which inactivates NOTCH1 expression through the transcriptome regulation of activating transcription factor 3 (ATF3). N‐acetylornithine delivery displays a proangiogenic therapeutic effect in the ischemic models. The therapeutic effects of FMO2 and N‐acetylornithine can also be recapitulated in human ECs. These findings provide insights into the proangiogenic mechanisms underlying FMO2 and N‐acetylornithine, revealing potential targets to treat ischemic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.
- Breast Cancer Center, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
- State Key Laboratory of Transvascular Implantation Devices, Hangzhou, 310009, China.
- Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, 310009, China.
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
- Transvascular Implantation Devices Research Institute, Hang Zhou, 310053, China.
ORCID-Profile: Xinyang Hu
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Central Guidance on Local Science and Technology Development Fund of Zhejiang Province
- Transvascular Implantation Devices Research Institute
- Binjiang Institute of Zhejiang University
- Key R&D projects of Zhejiang Province
- Fundamental Research Funds for the Central Universities
- National Key Research and Development Program of China
Zitieren
APA
Wang, J., Xu, Y., Wu, X., Li, M., Xiao, C., Fu, Z., Chen, Y., Li, Q., Ruan, Y., Zhao, J., Zhong, Z., Chen, J., Zhu, W., Nan, J., Ni, C., & Hu, X. (2025). FMO2 Promotes Angiogenesis via Regulation of N‐Acetylornithine. Advanced Science, 12(48). https://doi.org/10.1002/advs.202506618
Vancouver
Wang J, Xu Y, Wu X, Li M, Xiao C, Fu Z, et al. FMO2 Promotes Angiogenesis via Regulation of N‐Acetylornithine. Advanced Science. 2025;12(48). doi:10.1002/advs.202506618
BibTeX
@article{Wang2025,
author = {Wang, Jingyi and Xu, Yinghui and Wu, Xianpeng and Li, Mo and Xiao, Changchen and Fu, Zaiyang and Chen, Yongjian and Li, Qingju and Ruan, Yating and Zhao, Jing and Zhong, Zhiwei and Chen, Jinghai and Zhu, Wei and Nan, Jinliang and Ni, Cheng and Hu, Xinyang},
title = {FMO2 Promotes Angiogenesis via Regulation of N‐Acetylornithine},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {48},
doi = {10.1002/advs.202506618}
}
EUVIMED